Clinical Study Articles & Analysis

Through the years we have heard from many T-Stat users that they would like to collect their case data, review and present their findings. The transferring of data was limited to physically doing this on the T-Stat with a thumb drive. Now we have a new feature that is built into our remote access web application OnCall. If you want to collect your data you can easily request this in ...

By Spectros Medical Devices Inc.

Gelmetix is happy to announce a clinical study has been approved by the French Medical Authorities to investigate the benefit of the injection of the DXM gel to help alleviating pain from Chronic Lower Back pain patients. Pr Jean Charles Le Huec, from Bordeaux, France will drive the study as Principal Investigator. Information can be obtained at Polyclinique Bordeaux Nord in France. ...

By Gelmetix Limited

Within FAITH, a large number of parties are pooling their expertise and experiences in the field of frailty. Together FAITH provides more insight, practice-oriented knowledge, evidence-based interventions and conducts research into application in a personalized approach with an eye for the possibilities of technology and eHealth. Under FAITH umbrella, Balanseat is initiating a clinical study on ...

By Balanseat

ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...

By ImCare Biotech, LLC

Cytex was pleased to participate in the Life Sciences Showcase Conference, hosted virtually by the National Institutes of Health. This Conference, held in November 2020, is a leading forum for early stage innovators to present their companies to potential partners and investors. Cytex President and COO Bradley Estes, PhD., gave a virtual presentation on the current stage of Cytex implant ...

By Cytex Therapeutics, Inc.

PhysioAssist and the French CF patient association ‘Vaincre La Mucoviscidose’ have just signed a partnership to facilitate access to the use of the Simeox device at home. We are delighted about this partnership with the association Vaincre La Mucoviscidose, for allowing an easy access without engagement, as well as financial assistance by the association to the patients who wish to ...

By PhysioAssist

Progress Update December 27th, 2021 Year End Summary 2021 was a great year of progress for Second Heart Assist, Inc. We completed a large series of large animals with long duration use at Texas Heart Institute with great success. We believe we are set now to begin a cardio-renal syndrome clinical study with 24 hours circulatory assist support time in 1Q 2022. Our team believes we are in the ...

By Second Heart Assist, Inc.

Vektor Medical, Inc. announced the start of its clinical study to evaluate vMap™. Using patients who have previously undergone a clinically-indicated electrophysiology study and successful ablation, the purpose of this study is to clinically validate the use of vMap™ in providing arrhythmia/pacing hotspots for analysis by a physician. vMap™ has been designed as the next ...

By Vektor Medical, Inc.

Join us when we are expanding our unit with another Clinical Project Manager. In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and ...

By Scandinavian Biopharma

Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September. Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we believe we can do better with our more concentrated ...

By CanaQuest Medical Corp.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ET / 7:25 a.m. PT in Boston. The presentation will be accessible ...

By Sutro Biopharma Inc.

Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects ...

By Healx Ltd.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wedbush PacGrow Healthcare Conference’s panel discussion, “ADCs – Take Me to Your Tumor” on Wednesday, August 10, 2022, ...

By Sutro Biopharma Inc.

VANCOUVER, British Columbia – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round. The round is led by Fidelity Management & Research Company LLC., together with follow-on participation by funds and accounts advised by T. Rowe Price Associates, Inc. The new financing will be ...

By Kardium Inc.

Vivek Ramakrishnan will be presenting at AAO-HNSF on a poster titled: “Treatment of Rhinosinusitis with Topical Ultrasound”. The poster summarizes data from a clinical study supporting the use of therapeutic ultrasound for treatment in facial pain in patients diagnosed with chronic rhinosinusitis. The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) ...

By Bonutti Technologies

Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...

By Intrommune Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today it had passed the regulatory compliance review at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai. Clinical trials there and at three other centers are expected to begin this quarter. GTHP also ...

By Guided Therapeutics, Inc.

dBMEDx was selected as the winner of the 2016 Prime Health Challenge. The company received a $75,000 cash award and was selected by two hospital groups to host a pilot clinical study of the new BBS Revolution™ bladder scanner, which was first launched by the company in 2015. The BBS RevolutionTM is a next generation bladder scanner that offers nurses, for the first time, a fully automated ...

By dBMEDx

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Piper Sandler 34th Annual Healthcare Conference Format: Fireside Chat Date: Wednesday, ...

By Sutro Biopharma Inc.

LaunchPad Medical, Inc. announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient pilot clinical study to examine the safety and efficacy of Tetranite, the company's bone adhesive biomaterial, to immediately stabilize dental implants following tooth extractions. This study will focus specifically on anterior ...

By RevBio Inc.